http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011027363-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64f7db651a713f950523009581a897ab
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7084
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N33-08
filingDate 2010-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad477dda9f857e36c957b12971f34f95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afb9a77ace4dde912c5d2562dab95a23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca8f7dc2f80bd9e30bf97035a9109e57
publicationDate 2011-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2011027363-A3
titleOfInvention Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
abstract Use of high doses above 1 gm per day of ascorbic acid or the derivatives thereof for the treatment of neurodegenerative and neuro- muscular degenerative diseases and disorders, in particular amytrophic lateral sclerosis (ALS), multiple sclerosis (MS), alzheimer's disease (AD), parkinson's disease (PD), and muscular dystrophy (MD) is disclosed. Preferably the dose comprises mannitol which facilitates the delivery of ascorbic acid to the target cells in the brain. Still further the said dose comprises zinc citrate for preventing formation of kidney stones. Dose compositions for various routes of application such as oral, intravenous, intramuscular, nasal and in the form of transdermal patches are discussed.
priorityDate 2009-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5738873-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009176715-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007048296-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006149089-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226416273
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54676860
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87059419
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393724

Total number of triples: 35.